Why Your Most Likely Buyer Isn't in Your Country: Cross Border Exits for HealthTech, Health AI, MedTech, Digital Health Founders

The European healthcare technology and medical device ecosystem has entered an era of disciplined maturity. The speculative valuation inflation of the early 2020s has given way to a metrics-driven environment where strategic value is defined by clinical utility, regulatory resilience and technological defensibility. Within this landscape, European founders face a structural reality: domestic exit options are frequently constrained by fragmented national healthcare systems, localized reimbursement schemes, and limited domestic growth capital. 
  
Consequently, the premium buyer for a European HealthTech or MedTech asset is overwhelmingly cross-border, typically a US strategic acquirer, a pan-European consolidator, or a large German or Nordic corporate buyer.
  
While foreign acquirers command deeper balance sheets and offer significant valuation premiums—often 15% to 20% higher than domestic alternatives, cross-border transactions introduce deep operational and regulatory complexity. The acquisition process is no longer a straightforward negotiation of enterprise value; it is an intricate exercise in regulatory clearance and operational standardization. 
  
Foreign Direct Investment (FDI) screening regimes, such as the United Kingdom's National Security and Investment Act (NSI Act) and the European Union's revised FDI Screening Regulation (Regulation (EU) 2026/1386), routinely extend transaction timelines to between 12 and 30 weeks. Simultaneously, evolving health data sovereignty mandates, exemplified by the European Health Data Space (EHDS) Regulation—require targets to maintain localised compliance while presenting an architecture that can be integrated globally.
  
To capture top-tier cross-border valuations, European health founders must make their organizations internationally legible long before entering an M&A process. 
  
This report provides an analysis of cross-border exit dynamics, dissecting buyer motivation, regulatory screening mechanisms, data governance mandates, and accounting and operational alignment strategies.

https://www.healthcare.digital/single-post/cross-border-exits-for-healthtech-health-ai-medtech-digital-health-founders-why-your-most-likely